Dexamethasone proved to be a breakthrough in therapy COVID-19

Cheap and widespread drug dexamethasone has successfully passed clinical studies among patients hospitalized with coronavirus infection. As shown by the results of the RECOVERY studies, application of dexamethasone for about a third of the reduced mortality among patients on mechanical ventilation because of COVID-19, writes Nature.

A randomized clinical trial RECOVERY was initiated in the UK in March 2020. It has become one of the largest research therapy coronavirus infection – it took part 2.1 thousand patients receiving dexamethasone, as well as 4.3 thousand patients receiving standard therapy COVID-19.

The greatest efficiency of dexamethasone was observed among patients with severe infection: mortality among patients on mechanical ventilation decreased by 35%, and among patients receiving supplemental oxygen at 20%. While the steroid drug did not help patients with mild form of coronavirus infection.

After obtaining convincing results KEY the UK government announced the immediate approval of the use of dexamethasone in patients hospitalized with COVID-19.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]